** Shares of insulin delivery device maker Beta Bionics BBNX.O jump as much as 41.2% in their Nasdaq debut
** Stock opens for trading at $22, valuing the Irvine, California-based company at $943.6 mln
** BBNX sold 12 mln shares, 60% more than initially offered, at the top end of its marketed range of $16 and $17 to raise $204 mln
** IPO was twice upsized and follows medical device maker CeriBell's CBLL.O strong debut last year, underscoring a gradual recovery in medtech listings
** BBNX's strong show comes in the aftermath of underwhelming debuts by major IPO candidates including LNG exporter Venture Global VG.N and pork producer Smithfield Foods SFD.O
** BofA Securities, Piper Sandler, Leerink Partners, Stifel and Lake Street were the underwriters for the offering
** Asset manager Wellington Management, an existing Beta shareholder, had agreed to purchase $17 million worth of the company's shares in a concurrent private placement at the IPO price
(Reporting by Arasu Kannagi Basil in Bengaluru)
((ArasuKannagi.Basil@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。